BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 10, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vyvanse lisdexamfetamine regulatory update

FDA approved an updated label for once-daily ADHD drug Vyvanse lisdexamphetamine to include supplemental efficacy data showing significant improvement in attention...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >